cyc 202 has been researched along with su 5402 in 1 studies
| Studies (cyc 202) | Trials (cyc 202) | Recent Studies (post-2010) (cyc 202) | Studies (su 5402) | Trials (su 5402) | Recent Studies (post-2010) (su 5402) |
|---|---|---|---|---|---|
| 979 | 7 | 393 | 191 | 0 | 77 |
| Protein | Taxonomy | cyc 202 (IC50) | su 5402 (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.1867 | |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | 0.2675 | |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | 2.0262 | |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | 0.1867 | |
| Fibroblast growth factor receptor 1 | Mus musculus (house mouse) | 10 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.1136 | |
| Vascular endothelial growth factor receptor 1 | Mus musculus (house mouse) | 0.4 | |
| Mu-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.02 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elbaum, D; Lydon, NB; Toledo, LM | 1 |
1 review(s) available for cyc 202 and su 5402
| Article | Year |
|---|---|
The structure-based design of ATP-site directed protein kinase inhibitors.
Topics: Adenosine Triphosphate; Adenylyl Imidodiphosphate; Anthraquinones; Binding Sites; Catalytic Domain; Cyclin-Dependent Kinases; Drug Design; Enzyme Inhibitors; Humans; Kinetin; Piperazines; Protein-Tyrosine Kinases; Purines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Growth Factor; Roscovitine; Staurosporine; Structure-Activity Relationship | 1999 |